Large Molecule Patents
Lucentis is a drug owned by Genentech, Inc.. It is protect by 8 US patents. Given below is the list of those patents along with their expiration dates.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10112994 | GENENTECH, INC. | Methods of producing two chain proteins in bacteria |
Nov, 2035
(10 years from now) | Active |
| US9765379 | GENENTECH, INC. | Harvest operations for recombinant proteins |
Mar, 2034
(9 years from now) | Active |
| US10421984 | GENENTECH, INC. | Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele |
Sep, 2033
(8 years from now) | Active |
| US8383773 | GENENTECH, INC. | Protein product and method for reducing biomass-biomass interactions |
Dec, 2023
(1 year, 10 days ago) |
Expired |
| US6921659 | GENENTECH, INC. | Protease-deficient cells |
Oct, 2023
(1 year, 2 months ago) |
Expired |
| US9688775 | GENENTECH, INC. | System for antibody expression and assembly |
Dec, 2022
(1 year, 11 months ago) |
Expired |
| US6828121 | GENENTECH, INC. | Bacterial host strains |
Jul, 2022
(2 years ago) |
Expired |
| US6716602 | GENENTECH, INC. | Metabolic rate shifts in fermentations expressing recombinant proteins |
Nov, 2021
(3 years ago) |
Expired |
Lucentis's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
About Lucentis
Active Ingredients:
Lucentis contains Ranibizumab as an active ingredient
Approval Date:
Lucentis was first approved for market use on 30 Jun, 2006.
Dosage:
Lucentis is available in 2 strengths and the following dosage forms are - Injection form for Intravitreal use, Injection form for Intravitreal use.
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG/ML (0.5MG/0.05ML) | Injection | Rx | Intravitreal |
| 6MG/ML (0.3MG/0.05ML) | Injection | Rx | Intravitreal |
| 6MG/ML (0.3MG/0.05ML) | Injection | Rx | Intravitreal |
| 6MG/ML (0.3MG/0.05ML) | Injection | Rx | Intravitreal |
| 10MG/ML (0.5MG/0.05ML) | Injection | Rx | Intravitreal |
| 10MG/ML (0.5MG/0.05ML) | Injection | Rx | Intravitreal |
| 10MG/ML (0.5MG/0.05ML) | Injection | Rx | Intravitreal |
| 6MG/ML (0.3MG/0.05ML) | Injection | Rx | Intravitreal |